Associate Research Scientist
Department of Genetics
Xinghua (Victor) Pan obtained his M.D. degree from the Southern Medical University (previously called First Military Medical University), Guangzhou, China and earned his Ph.D. degree from the Institute of Genetics, Fudan University School of Life Science, Shanghai, China in 1993. His Ph.D. research was on the genetic associations between HLA and SLE and myasthenia gravis. After receiving his Ph.D. degree he worked as a Postdoctoral Research Associate at the National Key Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), identifying a candidate tumor suppressor gene with a grant support from The China Postdoctoral Science Foundation. Beginning in December 1994, he served as Associate Professor in Genetics in the Department of Biology, Second Military Medical University, Shanghai, China, where he earned his grant from the National Natural Science Foundation (NNSF) of China, with which he established nm23 transgenic mouse and elucidated its effect on hepatocarcinoma. In addition, he studied EBV BHRF1 on nasopharyngeal carcinoma, reconstructed the phylogenetic tree of mammalian MHC DQA alleles based on nucleotide substitution and codon usage, and found the role of positive selection in maintaining their polymorphism. In 1997, Dr. Pan joined Dr. Sherman Weissman’s laboratory in the Department of Genetics, Yale University School of Medicine, and developed an approach (Gadav) globally scanning the DNA mutations. From 2000 to 2004, he worked for Molecular Staging Inc. as a Research Scientist and Enzymatic Leader, and substantially contributed to the development of a kit for whole-genome-amplification (WGA), REPLIg, which is currently used world-wide and regarded as one of the best WGA technologies. In 2004, he obtained his current position as an Associate Research Scientist, working with Dr. Weissman, and in recent years he has been focusing on the development of the technologies for functional studies for single and low quantity of cells, especially single cell WGA, whole transcriptome amplification, and CpG methylation profiling, for which he conceived and is supported currently by a NIH R21 grant. Prior to this, he obtained a pilot grant from NIH via the Yale Skin Diseases Research Core Center (YSDRCC). These technologies combining with other advanced platforms are being applied in iPS, ESC and adult stem cells (ASC, including hematopoietic stem cells, mesenchymal stem cells), neurons and cancers.
His research is on functional genomics, focusing on the development and application of functional genomics technologies for analysis of single cells and low quantity of cells. These approaches include whole DNA pool amplification, whole mRNA transcriptome amplification, CpG methylation pattern scanning, DNase hypersensitive and resistant sites profiling, and telomere size analysis. Combining these technologies with second generation sequencing and microfluidic platform, and collaborating with other research teams, his group explores the genomic and epigenomic mechanism for reprogramming and transdifferentiation of human induced pluripotent stem cells (iPS), differentiation of embryo stem cells (ESCs) and adult stem cells (ASC, including hematopoietic stem cells, mesenchymal stem cells), molecular regulation underlying sensory neurons, embryo development and carcinogenesis.